3 unchanged sentences
In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
−Removed: The following table summarizes the activity, by month, during the three months ended June 30, 2021:
+Added: The following table summarizes the activity, by month, during the three months ended September 30, 2021:
Period Total Number of
7 unchanged sentences
Purchased Under
−Removed: April 25,977 $ 3.03 $ 5,808,276
−Removed: May 38,459 2.84 5,698,887
−Removed: June 93,969 (1)
+Added: July 39,264 $ 3.28 $ 5,273,299
+Added: August 24,424 2.98 5,200,518
+Added: September 12,720 (1)
2.84 5,164,448
−Removed: Total 158,405
(1) Of this amount, 281 shares were repurchased directly through private purchases at the then-current fair market value of common stock.
−Removed: 10.1 Employment Agreement, dated May 14, 2021, effective as of May 17, 2021, by and between John Hamm and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.16 of the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-33637) as filed with the SEC on May 14, 2021 .
+Added: 10.1* Fourth Amendment to Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement, dated as of October 28, 2021, by and between Cumberland Pharmaceuticals Inc.
+Added: and Pinnacle Bank .
31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
13 unchanged sentences
Cumberland Pharmaceuticals Inc.
−Removed: August 13, 2021 By:
+Added: November 12, 2021 By:
/s/ John Hamm
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.